Fresh Tracks Therapeutics (Fresh Tracks Therapeutics) Interest Expense : $-0.01 Mil (TTM As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Fresh Tracks Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Fresh Tracks Therapeutics's interest expense for the three months ended in Dec. 2023 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.01 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Fresh Tracks Therapeutics's Operating Income for the three months ended in Dec. 2023 was $ -1.65 Mil. Fresh Tracks Therapeutics's Interest Expense for the three months ended in Dec. 2023 was $ 0.00 Mil. Fresh Tracks Therapeutics has no long-term debt ⁽¹⁾. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Fresh Tracks Therapeutics Interest Expense Historical Data

The historical data trend for Fresh Tracks Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fresh Tracks Therapeutics Interest Expense Chart

Fresh Tracks Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-2.10

-0.07

-0.01

Fresh Tracks Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Fresh Tracks Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01 Mil.

Fresh Tracks Therapeutics (OTCPK:FRTX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Fresh Tracks Therapeutics's Interest Expense for the three months ended in Dec. 2023 was $0.00 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-1.65 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $0.00 Mil.

Fresh Tracks Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Fresh Tracks Therapeutics had no long-term debt ⁽¹⁾.

The higher the ratio, the stronger the company's financial strength is.

Fresh Tracks Therapeutics (Fresh Tracks Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fresh Tracks Therapeutics Inc (OTCPK:FRTX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

5777 Central Avenue, Suite 102, Boulder, CO, USA, 80301

Website

https://www.frtx.com

Fresh Tracks Therapeutics Inc is a clinical-stage pharmaceutical company striving to transform patient lives through the development of innovative and differentiated prescription therapeutics.

Executives

Monica E. Luchi	officer: Chief Medical Officer	430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016
Reginald L Hardy	director, officer: CHAIRMAN OF THE BOARD
David R. Mcavoy	officer: General Counsel and CCO	C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Deepak Chadha	officer: Chief Research & Dev. Officer	5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Vijay B Samant	director	10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Jose Breton	officer: Chief Accounting Officer	5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Robert Busard Brown	director, officer: Chief Executive Officer	5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Andrew D Sklawer	officer: COO and Secretary	5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Dennison T Veru	director	C/O PALIDADE CAPITAL, ONE BRIDGE PLAZA NORTH #695, FORT LEE NJ 07024
Marchio Albert N Ii	officer: Chief Financial Officer
Gary A Lyons	director	12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Sanjeev Ahuja	officer: Chief Medical Officer	121 3RD STREET NW, CARMEL IN 46032
Adam Scott Levy	officer: Chief Business Officer	C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, #100, BOULDER CO 80301
William Ju	director	5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
R Michael Carruthers	officer: Chief Financial Officer	3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301